Breast Cancer

The phase 3 TORCHLIGHT study, examining toripalimab and paclitaxel, has become the first study in China to achieve positive outcomes with immunotherapy for triple-negative breast cancer.

Patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at a high risk of relapse who are eligible for treatment with abemaciclib can be identified via nodal status as well as tumor size and grade.

Experts discuss updates in HR+ breast cancer, with a focus on treatment options before and after progression and emerging data.

Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.

The FDA has approved Guardant 360 CDx as a companion diagnostic for elacestrant in patients with ESR1-mutant, estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.

Expert panelists consider the appropriate use of PARP and immune checkpoint inhibitors, respectively, in the setting of HR+ metastatic breast cancer.

“Nonetheless, we saw tremendous benefits for these patients, patients who didn’t benefit from other treatments, and it was exciting to be involved with this early research.”

Richard L. Martin III, MD, MPH, and Stephen Schleicher, MD, MBA, share a perspective on rural cancer care.

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer can now receive elacestrant as treatment following the FDA’s approval of the agent.

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

The European Commission approval for trastuzumab deruxtecan in HER2-low metastatic breast cancer is based on data from the phase 3 DESTINY-Breast04 trial.

A brief review of Trop-2 directed therapy and its role in the HR+ metastatic breast cancer treatment landscape.

Centering discussion on HER2-targeted trastuzumab deruxtecan, experts reflect on the presence of HER2-low metastatic breast cancer and optimal treatment strategies.

The panel closes their discussion by musing on the future of HER2 mBC treatments.

Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.

Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.

Cisplatin plus veliparib appears to improve progression-free survival among patients with BRCA-like metastatic triple-negative breast cancer, but not in those with non–BRCA-like metastatic breast cancer.

After briefly addressing resistance to endocrine therapy, expert panelists broadly review novel treatment modalities in the setting of HR+ metastatic breast cancer.

Expert perspectives review a case of relapsed HR+ metastatic breast cancer and consider treatment options available in the second line and beyond.

The investigational drug CFI-402257 alone and in combination with fulvestrant received fast track designation from the FDA for patients with estrogen receptor–positive, HER2-negative advanced breast cancer.

A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.

Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.

A contingent of patients with a type of lung cancer and breast cancer continues to experience responses to treatment with zotatifin, according to updated study findings.

Highlights from key clinical data informing the selection of targeted therapy in particular subsets of patients with HR+ breast cancer.

Comprehensive insight to the selection of CDK4/6 inhibitors as first-line therapy for patients with metastatic HR+ breast cancer, followed by a brief review of available endocrine partners.

A discussion on the prevalence and treatment difficulties of leptomeningeal metastases in HER2+ mBC.

The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.